Bern-based LEM Surgical secures €23.6 million Series B to ready robotic system for FDA submission
Summary
This substantial funding boost is attributed to the enthusiastic participation of new investors from both the United States and Switzerland. The infusion of capital is strategically earmarked to propel the advancement of LEM Surgical’s product development initiatives and readiness for FDA submission in the second half of 2024. Yossi Bar, founder and CEO of LEM Surgical, said: “Our goal is to revolutionize the experience for surgeons, clinical teams, and hospitals engaged in robotic surgery. The primary focus of its development efforts is centered around surpassing the capabilities of existing robotic platforms for spine surgery. The company was founded in 2021 by Prof. Dr. Stefan Weber (CEO, CAScination AG), Marco Matulic (CTO, CAScination AG), Simon Michel (CEO, Ypsomed Group), Prof. Dr. Andreas Raabe (Director, Department of Neurosurgery, Inselspital Bern) and Yossi Bar (previously Director R&D at Mazor Robotics Ltd).
Funding
Review available funding amount, funding date, investors, and linked company information related to Bern-based LEM Surgical secures €23.6 million Series B to ready robotic system for FDA submission in the interactive ISVWorld profile.